Diagnosis and Treatment of Epigastric Abdominal Pain in Adolescents
Introduction to Diagnostic Possibilities
- The American Academy of Pediatrics suggests considering key diagnostic possibilities, including GERD, functional dyspepsia, peptic ulcer disease, and eosinophilic esophagitis, when evaluating an adolescent with epigastric pain after eating 1
First-Line Therapy for Ulcer-Like Dyspepsia and GERD
- The American College of Gastroenterology recommends full-dose PPI therapy with omeprazole 20 mg once daily as first-line therapy for ulcer-like dyspepsia 1
- The American Gastroenterological Association suggests a 4-8 week trial of single-dose PPI therapy for suspected GERD, with omeprazole administered 30-60 minutes before a meal for optimal effect 2
Treatment Duration and Follow-Up
- The American College of Gastroenterology recommends reassessing symptoms after a 4-8 week trial of omeprazole, and if symptoms resolve, tapering to the lowest effective dose 2
- If symptoms persist beyond 8-12 weeks despite PPI therapy, endoscopy should be considered rather than continuing empiric treatment, as suggested by the American Gastroenterological Association 2
Diagnosis of Non-Acid Related Disorders
- The European Society for Pediatric Gastroenterology, Hepatology and Nutrition suggests considering eosinophilic esophagitis (EoE) if symptoms do not respond to PPI therapy, which may require endoscopic diagnosis 3
- Functional dyspepsia of dysmotility-type may respond better to prokinetics than PPIs, as recommended by the American College of Gastroenterology 1
Important Considerations for Treatment
- A clinical response to PPI therapy does not necessarily rule out other conditions like EoE, as noted by the European Society for Pediatric Gastroenterology, Hepatology and Nutrition 3
- When considering PPI therapy for pediatric patients, first rule out other causes of symptoms, try conservative measures before medication, reserve acid suppression therapy for documented acid-related disorders, and ensure regular review of the ongoing indication for use, as recommended by guidelines from reputable medical societies such as the American Academy of Pediatrics 4, 5
- The American Academy of Pediatrics recommends using the lowest effective dose for the shortest duration necessary, regularly reviewing the need for continued therapy, documenting the specific indication for PPI use, considering step-down from twice-daily to once-daily dosing when possible 4, 5
PPI Dosage and Administration
- The recommended pediatric dosage of lansoprazole is 0.7-3.0 mg/kg/day for children aged 1 year and older, according to the Pediatrics journal guidelines 5
- For children under 5 years, other PPIs with established pediatric dosing include omeprazole (0.7-3.3 mg/kg/day, approved for ages 1 year and older), and esomeprazole (0.7-3.3 mg/kg/day) 5
- For children 5 years and older, fixed doses of 20 mg or 40 mg once daily have been studied, similar to adult dosing 5
- For children 1-5 years, approximately 0.6-1.2 mg/kg once daily has been studied, though this age group lacks FDA approval 5
- The following table summarizes the recommended PPI dosing for different age groups:
| Age Group | Recommended PPI Dosing | |
|---|---|---|
| 1 year and older | omeprazole (0.7-3.3 mg/kg/day), lansoprazole (0.7-3.0 mg/kg/day) | |
| 5 years and older | fixed doses of 20 mg or 40 mg once daily | |
| 1-5 years | approximately 0.6-1.2 mg/kg once daily (lacks FDA approval) | |
| under 1 year | not recommended due to lack of efficacy and potential for adverse effects | [5] |
- Junior Lanzol is available in formulations that can be sprinkled onto soft foods or select juices, and can be administered through a nasogastric tube (≥8 French) 5
- Junior Lanzol is typically available in child-friendly formulations, including sprinkle capsules and orally disintegrating tablets, which can be used for children who cannot swallow pills 5
Safety and Adverse Effects
- Proton pump inhibitors (PPIs) should be reserved for children with documented acid-related disorders, not for non-specific symptoms, as recommended by the American Academy of Pediatrics, although this is based on expert opinion rather than a specific reference 5
- The American Academy of Pediatrics expresses significant concern about the dramatic increase in PPI prescriptions for infants, noting that placebo-controlled trials in infants have not demonstrated superiority of PPIs over placebo for reduction in irritability, and may be associated with increased risk of lower respiratory tract infections, gastroenteritis, candidemia, and necrotizing enterocolitis in preterm infants 5
- Pantoprazole and other PPIs carry risks including headaches, diarrhea, constipation, and nausea (up to 14% of children), as well as potential long-term adverse effects such as increased risk of lower respiratory tract infections, especially in infants 5
- For infants under 1 year, pantoprazole is not recommended due to lack of efficacy and potential for adverse effects, and other PPIs should be used with caution and only when absolutely necessary 5